In this single-arm phase-2 trial, patients will get 2 weeks of COCP’s non-nuke, CC-31244 with GILD’s SOF/VEL, then 4 weeks of SOF/VEL alone. COCP does not have a collaborative agreement with GILD, as far as I know.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”